Prelude Therapeutics Inc. (PRLD): Price and Financial Metrics
PRLD Price/Volume Stats
| Current price | $3.87 | 52-week high | $6.89 |
| Prev. close | $3.87 | 52-week low | $1.66 |
| Day low | $3.87 | Volume | 28,584 |
| Day high | $4.13 | Avg. volume | 66,328 |
| 50-day MA | $4.40 | Dividend yield | N/A |
| 200-day MA | $3.63 | Market Cap | 212.54M |
PRLD Stock Price Chart Interactive Chart >
Prelude Therapeutics Inc. (PRLD) Company Bio
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Latest PRLD News From Around the Web
Below are the latest news stories about PRELUDE THERAPEUTICS INC that investors may wish to consider to help them evaluate PRLD as an investment opportunity.
AI Meets Biotech: 3 Top Stocks Transforming Medical ScienceThe AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. |
Prelude Therapeutics Announces $25 Million Private PlacementWILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company. Proceeds from the private placement will be used to primarily fund the continued advancement of its SMARCA2 portfolio, for working ca |
Shell's (SHEL) Prelude LNG Facility to Restart in DecemberShell's (SHEL) Prelude LNG facility, nearing the completion of extensive maintenance, is poised for a strategic comeback, aiding the global LNG market. |
Prelude Therapeutics Insiders Are Down US$149k But Regain Some LossesInsiders who bought US$263.0k worth of Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) stock in the last year have... |
Q3 2023 Abcellera Biologics Inc Earnings CallQ3 2023 Abcellera Biologics Inc Earnings Call |
PRLD Price Returns
| 1-mo | -16.05% |
| 3-mo | 15.87% |
| 6-mo | 113.81% |
| 1-year | -34.07% |
| 3-year | -88.81% |
| 5-year | N/A |
| YTD | -9.37% |
| 2023 | -29.30% |
| 2022 | -51.49% |
| 2021 | -82.60% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...